Loading...

WHAT’S NEW?

Integra Holdings Closes $3 Million Investment from Guangxi Wuzhou Pharmaceutical Group

Jerusalem, Israel, December 8, 2014 - Integra Holdings, the biotechnology holdings company of Yissum, the technology transfer company of the Hebrew University of Jerusalem ...
December,09 2014

Avraham Pharmaceuticals Raises $4.5 Million in Additional Investment Led by Yissum

The capital is intended for the on-going Phase 2b clinical trial of ladostigil, a novel molecule for treatment of mild cognitive impairment; next interim analysis is expected in Q3 2015; final results expected in Q3 2016 ...
September,17 2014

Atox Bio Closes $23 Million Investment

Funds will be used to advance development of AB103, a novel therapy for the treatment of necrotizing soft tissue infections ...
July,24 2014

Tiltan Pharma Raises $1.5 Million

The capital is intended for the completion of the ongoing Phase 2 clinical trial of TL-118, for the treatment of metastatic pancreatic cancer ...
February,01 2014

Atox Bio Publishes Data Demonstrating the Broad Therapeutic Effect of its Flagship Product in Treating “Flesh Eating Bacteria”

Findings published in the Journal of Infectious Diseases ...
April,01 2013

Avraham Pharmaceuticals Closes an Additional Investment Round of Approximately $6 Million by Yissum, Pontifax and Clal Biotechnology Industries

The capital is intended for the on-going Phase II clinical trial of ladostigil, a novel molecule for treatment of mild cognitive impairment; interim analysis is expected in H1 2014 ...
February,01 2013

Tiltan Pharma Announces Enrollment of First U.S. Patient in a Phase 2 Clinical Trial of TL-118, Anti-Angiogenic Treatment for Metastatic Pancreatic Cancer

White Plains Hospital is the first U.S. site to offer this innovative treatment to cancer patients ...
November,01 2012

Yissum Announces Formation of Integra Holdings, a Biopharmaceutical Holding Company

Integra Holdings closes U.S. $ 7.0 million private financing ...
October,01 2012

Avraham Pharmaceuticals Announces Commencement of a Phase 2 Study of Ladostigil for the Treatment of MCI

Enrollment has been completed in a Phase 2 study of ladostigil for the treatment of Alzheimer's Disease and results expected in Q4 2012 ...
May,01 2012

Tiltan Pharma Commences Phase 2 Clinical Study of Anti-Angiogenic Treatment for Pancreatic Cancer

Jerusalem Israel - February 13, 2012 - Tiltan Pharma Ltd. today announced that it has commenced a Phase 2 clinical trial of its anti-angiogenic product TL-118 for the treatment of pancreatic cancer. ...
February,02 2012

Yissum, Pontifax, Clal Biotechnology Industries, TRDF and Other Investors Complete Additional Investment Round of $3 Million in Avraham Pharmaceuticals

Yissum will now maintain 30% holding share in Avraham Pharmaceuticals, which will be transferred to its forthcoming biotech holdings company ...
November,14 2011

Atox Bio raises $2.1 Million to advance development of AB103, a novel therapy for the treatment of severe bacterial infections.

Rehovot Israel - October 13, 2010 - Atox Bio Inc. today announced that it has raised $2.1 million to advance the development of AB103, a clinical stage therapeutic being developed for the treatment of ...
October,13 2010

Atox Bio, a Spin-Off of Yissum, Announces Dosing of First Subject in Phase 1 study of AB103, a Novel Immunomodulator for the Treatment of Severe Bacterial Infections and Sepsis

Rehovot Israel - September 15, 2010 - Atox Bio, a Spin-Off of Yissum, today announced that it successfully completed the dosing of the first subject in its phase 1 clinical study of AB103 ...
September,01 2010

Atox Bio and Fast-Track Drugs & Biologics Sign an R&D Collaboration Agreement for the Development of Therapeutics for Sepsis and Septic Shock

He collaboration is funded by the Israel-U.S. binational BIRD Foundation ...
June,01 2009